| atabecestat (JNJ-54861911) / J&J |
NCT01827982: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo |
|
|
| Completed | 1 | 56 | Europe | JNJ-54861911 1mg, JNJ-54861911 3 mg, JNJ-54861911 9 mg, JNJ-54861911 27 mg, JNJ-54861911 81 mg, JNJ-54861911 160 mg, JNJ-54861911 tbd, Placebo | Janssen Research & Development, LLC | Healthy | 07/13 | 07/13 | | |
NCT02260700: A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants |
|
|
| Completed | 1 | 12 | Europe | JNJ-54861911 (Treatment A), JNJ-54861911 (Treatment B), JNJ-54861911 (Treatment C) | Janssen Research & Development, LLC | Healthy | 11/13 | 11/13 | | |
NCT01887535: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants |
|
|
| Completed | 1 | 70 | Europe | JNJ-54861911 3 mg, JNJ-54861911 10 mg, JNJ-54861911 30 mg, JNJ-54861911 80 mg, JNJ-54861911 25 mg, Placebo | Janssen Research & Development, LLC | Healthy | 12/13 | 12/13 | | |
NCT02180269: A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants |
|
|
| Completed | 1 | 24 | Japan | JNJ-54861911 (25 mg), JNJ-54861911 (50 mg), JNJ-54861911 (100 mg), Placebo | Janssen Pharmaceutical K.K. | Healthy | 08/14 | 08/14 | | |
NCT02197884: A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants |
|
|
| Completed | 1 | 13 | Europe | JNJ-54861911, 25 mg, Itraconazole 200 mg, Clarithromycin 500 mg | Janssen Research & Development, LLC | Healthy | 09/14 | 09/14 | | |
NCT02211079: A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates |
|
|
| Completed | 1 | 16 | Europe | JNJ-54861911, Caffeine, Midazolam, Tolbutamide | Janssen Research & Development, LLC | Healthy | 11/14 | 11/14 | | |
NCT01978548: A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease |
|
|
| Completed | 1 | 45 | Europe | JNJ-54861911 10 mg, JNJ-54861911 50 mg, Placebo | Janssen Research & Development, LLC | Alzheimer Disease | 04/15 | 04/15 | | |
